Opendata, web and dolomites

PET-AlphaSy SIGNED

PET Imaging of Alpha-Synuclein Fibril Formation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PET-AlphaSy project word cloud

Explore the words cloud of the PET-AlphaSy project. It provides you a very rough idea of what is the project "PET-AlphaSy" about.

probes    tailoring    unmet    pharmaceutical    market    until    tracer    parkinson    tomography    tracers    aid    disease    hallmark    scientists    presently    radioisotope    patient    physicians    nuclear    effectiveness    spanning    diseases    alpha    insufficient    successful    synuclein    industry    too    imaging    techniques    start    strategy    molecular    interdisciplinary    modifying    favorable    individual    ways    emission    pet    drug    apparent    protein    rely    pathogenic    expensive    diagnose    pharmacy    academic    limiting    diagnosis    positron    personalized    generation    skills    trial    treatment    aggregates    error    fibril    train    goals    fashion    situation    rate    biology    thought    treatments    validated    respect    critical    assembled    stage    enterprises    time    visualization    healthcare    medicinal    frontline    leads    scientific    medicine    reduce    chemistry    gmp    pd    stages    entrepreneurial    radiopharmaceutical    training    ineffective    pathology   

Project "PET-AlphaSy" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 4˙100˙370 €
 EC max contribution 4˙100˙370 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 892˙566.00
2    STICHTING VUMC NL (AMSTERDAM) participant 796˙859.00
3    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 758˙365.00
4    UPPSALA UNIVERSITET SE (UPPSALA) participant 563˙965.00
5    REGION HOVEDSTADEN DK (HILLEROD) participant 297˙522.00
6    BIOARCTIC AB SE (STOCKHOLM) participant 281˙982.00
7    ELYSIA BE (LIEGE) participant 256˙320.00
8    JOHANNES GUTENBERG-UNIVERSITAT MAINZ DE (MAINZ) participant 252˙788.00
9    Eckert & Ziegler Eurotope GmbH DE (Berlin) partner 0.00
10    H. LUNDBECK AS DK (VALBY) partner 0.00
11    ION BEAM APPLICATIONS SA BE (OTTIGNIES LOUVAIN LA NEUVE) partner 0.00
12    NOVO NORDISK A/S DK (BAGSVAERD) partner 0.00
13    PMOD TECHNOLOGIES GMBH CH (ADLISWIL) partner 0.00
14    POSITRONPHARMA SA CL (SANTIAGO) partner 0.00
15    TAGWORKS PHARMACEUTICALS BV NL (Eindhoven) partner 0.00
16    UNIVERSITE DE LIEGE BE (LIEGE) partner 0.00

Map

 Project objective

Too often, physicians have to rely on a trial and error strategy until the most effective treatment for an individual patient is identified. This leads to a critical loss of time, making the healthcare system ineffective and expensive. In respect to drug development, a high failure rate is apparent at all stages of development and ways to reduce this have high priority for the pharmaceutical industry. To this end, drug development and medicinal treatment need to be more personalized and molecular imaging techniques, in particular Positron Emission Tomography (PET) imaging, can be used to achieve this by 1) evaluating the effectiveness of new treatments emerging from the pharmaceutical industry, 2) improving the ability to diagnose diseases, and 3) aid tailoring the treatment based on individual patient pathology. A limiting factor to develop new effective PET imaging probes is the insufficient number of radiopharmaceutical scientists presently available. Our consortium has assembled 6 radiopharmaceutical frontline academic and 10 non-academic partners to address this problem and train the next generation of radiopharmaceutical scientists. Our training will be focused on an unmet scientific need for Parkinson’s Disease (PD). Fibril formation of protein α-synuclein is thought to be the hallmark for PD, but presently, there are no validated PET tracers available for visualization of pathogenic aggregates of this protein. Our scientific goal is to develop such tracer. A successful tracer will have a strong impact on PD-diagnosis and facilitate the development of effective disease modifying treatments. To reach our goals, it is necessary to train our early stage researchers in a highly interdisciplinary fashion spanning from chemistry, over biology, GMP and pharmacy to nuclear medicine. Furthermore, this consortium will train entrepreneurial skills and facilitate start up new enterprises in the current favorable radioisotope market situation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PET-ALPHASY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PET-ALPHASY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

CALIPER (2019)

Creating Granular Materials Experts by Developing Experimental Calibrations for Computational Methods

Read More  

EDIFY (2018)

European Doctorate in Indium Phosphide PIC Fabrication Technology

Read More  

MARCIUS (2019)

MARie Curie Intelligent UltraSound

Read More